Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Recent Developments in Cancer Vaccines

Karolina Palucka, Hideki Ueno and Jacques Banchereau
J Immunol February 1, 2011, 186 (3) 1325-1331; DOI: https://doi.org/10.4049/jimmunol.0902539
Karolina Palucka
*Baylor Institute for Immunology Research, Baylor University Medical Center, Dallas, TX 75204;
†Sammons Cancer Center, Baylor University Medical Center, Dallas, TX 75204;
‡Department of Gene and Cell Medicine Immunology Institute, Mount Sinai School of Medicine, New York, NY 10029; and
§Department of Medicine, Immunology Institute, Mount Sinai School of Medicine, New York, NY 10029
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hideki Ueno
*Baylor Institute for Immunology Research, Baylor University Medical Center, Dallas, TX 75204;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacques Banchereau
*Baylor Institute for Immunology Research, Baylor University Medical Center, Dallas, TX 75204;
‡Department of Gene and Cell Medicine Immunology Institute, Mount Sinai School of Medicine, New York, NY 10029; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The adoptive transfer of cancer Ag-specific effector T cells in patients can result in tumor rejection, thereby illustrating the immune system potential for cancer therapy. Ideally, one would like to directly induce efficient tumor-specific effector and memory T cells through vaccination. Therapeutic vaccines have two objectives: priming Ag-specific T cells and reprogramming memory T cells (i.e., a transformation from one type of immunity to another, for example, regulatory to cytotoxic). Recent successful phase III clinical trials showing benefit to the patients revived cancer vaccines. Dendritic cells (DCs) are essential in generation of immune responses, and as such represent targets and vectors for vaccination. We have learned that different DC subsets elicit different T cells. Similarly, different activation methods result in DCs able to elicit distinct T cells. We contend that a careful manipulation of activated DCs will allow cancer immunotherapists to produce the next generation of highly efficient cancer vaccines.

Footnotes

  • This work was supported by the National Institutes of Health (P01 CA084514, U19 AIO57234, R01 CA089440, and CA078846), the Dana Foundation, the Susan Komen Foundation, the Baylor Health Care System, the Baylor Health Care System Foundation, the Agence Nationale de Recherches sur le SIDA, and the Institut National de la Santé et de la Recherche Médicale. K.P. holds the Michael A. Ramsay Chair for Cancer Immunology Research. J.B. holds the Caruth Chair for Transplant Immunology Research.

  • Abbreviations used in this article:

    cDC
    classical dendritic cell
    DC
    dendritic cell
    LC
    Langerhans cell
    PROSTVAC
    poxviral-based vaccine targeting prostate-specific Ag
    Treg
    regulatory T cell.

  • Received July 6, 2010.
  • Accepted November 10, 2010.
  • Copyright © 2011 by The American Association of Immunologists, Inc.
View Full Text
PreviousNext
Back to top

In this issue

The Journal of Immunology: 186 (3)
The Journal of Immunology
Vol. 186, Issue 3
1 Feb 2011
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Advertising (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Recent Developments in Cancer Vaccines
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Recent Developments in Cancer Vaccines
Karolina Palucka, Hideki Ueno, Jacques Banchereau
The Journal of Immunology February 1, 2011, 186 (3) 1325-1331; DOI: 10.4049/jimmunol.0902539

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Recent Developments in Cancer Vaccines
Karolina Palucka, Hideki Ueno, Jacques Banchereau
The Journal of Immunology February 1, 2011, 186 (3) 1325-1331; DOI: 10.4049/jimmunol.0902539
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Conclusions
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Dicer and PKR as Novel Regulators of Embryonic Stem Cell Fate and Antiviral Innate Immunity
  • Innate and Adaptive Immunity in Noninfectious Granulomatous Lung Disease
  • Innate Immune Memory and the Host Response to Infection
Show more BRIEF REVIEWS

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2022 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606